Navigation Links
Genome-wide association study on Parkinson's disease finds public home at NIH

Data from one of the first genome-wide association studies (GWAS), which focused on Parkinsons diseases and was funded in part by The Michael J. Fox Foundation for Parkinsons Research (MJFF), is now being made available to researchers through the National Human Genome Research Institute (NHGRI) and the National Center for Biotechnology Information (NCBI), both of the National Institutes of Health (NIH). NHGRI hopes to speed up research by making previously unavailable GWAS data sets publicly available to the research community.

The study, conducted by researchers at Mayo Clinic in Rochester, Minn., in collaboration with scientists at Perlegen Sciences, Inc., in Mountain View, Calif., was the first genome-wide association study applied to Parkinsons disease. It was funded under MJFFs Linked Efforts to Accelerate Parkinsons Solutions (LEAPS) initiative.

Until now, the individual-level data from this study had been available only to a few researchers, said Teri Manolio, M.D., Ph.D., director of the NHGRI Office of Population Genomics. This is the first orphan data set NHGRI is adopting to make public through NCBI, but it certainly will not be the last. We appreciate the willingness of the LEAPS researchers and patients to share their data with the rest of the research community and hope it will increase our understanding of Parkinsons disease.

The raw data from a GWAS study is frequently useful to other researchers who may combine it with their own data to improve the analytical power and even make new discoveries. But such information may not be deposited in unregulated public databases because the data typically contain details that could be used to identify study volunteers, potentially violating their privacy. In order to protect the volunteers privacy, NIH requires the data submitters to remove identifying information (names, social security numbers, etc.). In addition, researchers who want to use the data must ask for permission and agree to other data use limitations, such as safeguarding participants privacy and using the data in ways consistent with consent agreements signed by study subjects. The researcher requests are then reviewed by a data access committee or DAC. Data access committees have been established at several NIH institutes that organize and support GWAS. Because this project was primarily supported by a private foundation, it lacked a DAC to review access requests, so it was considered an orphan data set.

NHGRIs data access committee recently agreed to adopt the study and manage the data access approval process so that the data could be made widely available while ensuring the appropriate protections for confidentiality and privacy.

Its wonderful that NHGRI has agreed to facilitate access to this data by researchers around the globe working on Parkinsons disease, said Demetrius Maraganore, M.D., a neurologist at Mayo Clinic and the lead principal investigator who provided the Mayo-Perlegen LEAPS data to the dbGaP database on behalf of his collaborators. Our hope is that these data will be used to make breakthroughs in the prevention and treatment of this devastating disease.

The Mayo-Perlegen LEAPS Collaboration study will be added to dbGaP, the database of Genotypes and Phenotypes ( operated by the National Library of Medicines National Center for Biotechnology Information. The dbGaP database contains individual-level data on genotype (an individuals genetic makeup), and phenotype (observable traits and characteristics). The Mayo-Perlegen LEAPS Collaboration is the second dataset on Parkinsons disease available through dbGaP. The first was the NINDS-Genome-Wide Genotyping in Parkinsons Disease: First Stage Analysis and Public Release of Data, which is available through dbGaP at It was supported by the National Institute of Neurological Disorders and Stroke (NINDS) and conducted by researchers at the National Institute of Aging, another component of NIH.

The Michael J. Fox Foundation is committed to spurring innovation by creating every possible opportunity for researchers to collaborate and share their knowledge," said Katie Hood, chief executive officer of The Michael J. Fox Foundation. "We are hopeful that NIH's initiative in hosting the Mayo-Perlegen data will accelerate efforts to identify genetic factors underlying Parkinson's disease."

Additional funding for the work was also provided by the National Institute of Environmental Health Sciences (NIEHS) and NINDS, both part of the NIH. The Mayo-Perlegen LEAPS Collaboration study was published online in September 2005 in the American Journal of Human Genetics.

For researchers who want to view the Mayo-Perlegen LEAPS Collaboration data, dbGaP offers two levels of access. The first is open access, where certain data are available without restriction, and the second is controlled access, which requires authorization. The open-access section allows users to view study documents that do not risk identifying individual participants, such as protocols and summaries of genotype and phenotype data. The controlled-access portion of the database allows approved researchers to download individual-level genotype and phenotype data from which the study participants personal identifiers, such as names, have been removed.

Providing the Mayo-Perlegen LEAPS Collaboration data through dbGaP will give researchers new opportunities to investigate genetic factors in Parkinsons disease, said Donald A.B. Lindberg, M.D., director of the National Library of Medicine. By sharing their data, the study investigators and study subjects are not only aiding in the research effort for Parkinsons disease, but they are helping provide the foundation for researchers to do analyses across multiple studies looking for genetic variations associated with health and disease.

NHGRIs DAC has agreed to manage data access for all genome-wide association studies submitted to dbGaP that are not associated with other NIH Institutes, including studies submitted by corporate entities. Taking on all these orphan studies will result in significantly more data being available through dbGaP and will greatly enhance the discovery opportunities for researchers mining these data, said NCBI Director David Lipman, M.D.

Researchers interested in accessing the Mayo-Perlegen LEAPS Collaboration study dataset should go to dbGaPs Web site and complete a request for access to the individual-level data at Information on data access request procedures is available through the dbGaP controlled access Web page, at

Although personally identifying information is not included in the database, concern remains that it may someday be possible to identify someone based on their genetic profile. For this reason only researchers agreeing not to attempt to identify individuals in the database will be given access to the data, as outlined in NIH's Policy for Sharing of Data Obtained in NIH Supported or Conducted Genome-Wide Association Studies (GWAS) available at

Researchers interested in submitting similar datasets to dbGaP should contact dbGaP staff at The institutional certification that NHGRI will require for submitting datasets is also described in NIHs Policy for Sharing of Data Obtained in NIH Supported or Conducted Genome-Wide Association Studies (GWAS) at the link above.


Contact: Geoff Spencer
NIH/National Human Genome Research Institute

Related medicine news :

1. Genomatix integrates genome-wide open chromatin from next generation sequencing
2. Genome-wide survey nets key melanoma gene
3. Researchers provide genetic associations from a genome-wide scan for cardiovascular disease traits
4. Texas Health Care Association Asks Texas Congressional Delegation to Sign Letter Urging House Budget Committee to Rescind Bush Medicare Cuts
5. New Jersey Hospital Association Presents Awards for Commitment to Healthcare
6. New Jersey Hospital Association Names New Chairman, Appoints Board Officers and New Members
7. Randy Jackson and the American Heart Association Educate Minneapolis Area about the Connection between Type 2 Diabetes and Cardiovascular Disease
8. Randy Jackson and the American Heart Association Educate Cincinnati Area Residents about the Connection between Type 2 Diabetes and Cardiovascular Disease
9. NutriSystem and Celebrities Team Up to Benefit the American Heart Association
10. New genetic association with schizophrenia found by researchers
11. Healthcare Businesswomens Association Names Genentechs Leonard Kanavy, Vice President, Commercial Operations as the 2008 Honorable Mentor
Post Your Comments:
(Date:6/25/2016)... ... ... closing of Bruton Memorial Library on June 21 due to a possible lice infestation, as ... of head lice: the parasite’s ability to live away from a human host, and to ... one in the event that lice have simply gotten out of control. , As lice ...
(Date:6/25/2016)... ... ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors in ... School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green Hospital ... at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train in ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from reveals ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
(Date:6/24/2016)... Fla. (PRWEB) , ... June 24, 2016 , ... Global ... Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition ... Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this year’s ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)...  Arkis BioSciences, a leading innovator in the ... cerebrospinal fluid treatments, today announced it has secured ... led by Innova Memphis, followed by Angel Capital ... Arkis, new financing will accelerate the commercialization of ... of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
Breaking Medicine Technology: